ALS Ice Bucket Challenge Progress
  • Sign up
  • |
  • Login
  • |
  • Find local services
  • |
  • |

 
Information about RADICAVA

 

The FDA has approved Radicava™ (edaravone), the first new treatment specifically for ALS in 22 years. The drug was approved by the FDA less than a year after Mitsubishi Tanabe Pharma Corporation submitted a New Drug Application. The only other approved treatment specifically for ALS, riluzole, was approved in 1995.

Please click the links on the right to find more information on Radicava and check back often for updates.

Important message about
Radicava prescription coverage

For those who have been denied coverage, we encourage you to request an Independent Medical Review (IMR). This review is conducted by, and under the authority and supervision of, the California Department of Managed Health Care. The process is simple and can be easily completed on-line in just a few minutes. By following this simple process, you will bring much needed awareness of the problem to those within our state government who have the authority to address the issue. By requesting an IMR, you are lending your voice to our efforts to ensure that everyone who wants access to Radicava can have it.

Step 1: Go to the Online IMR Complaint Form. From there, you can complete and submit the request form online, or via mail or fax.

Step 2: Please email or fax a copy of your IMR request form to our Care Services Assistant, Stacy Roberts, to sroberts@alsagoldenwest.org or (818) 865-8066 so that we can track the submissions.

Past Webinars

May 9, 2017 - Webinar: Download Slides / Watch a Recording

May 12, 2017- Webinar:Watch a Recording

The FDA has approved Radicava™, the first new treatment specifically for ALS in 22 years. The drug was approved by the FDA less than a year after Mitsubishi Tanabe Pharma America submitted a New Drug Application. The only other approved treatment specifically for ALS, riluzole, was approved in 1995. Please click the links below to find more information on Radicava and check back often for updates.

Past Webinars

May 9th Webinar:
Download Slides / Watch a Recording

May 12th Webinar:
Watch a Recording

Press Release


FAQ


Connect With Us

When you sign up with our chapter, you’ll learn how you can help secure more funding for ALS research, expand care and resources for people living with this disease and their families, and advance legislative priorities that are important to the entire ALS community.

Sign Up Today

Information about RADICAVA

 

The FDA has approved Radicava™ (edaravone), the first new treatment specifically for ALS in 22 years. The drug was approved by the FDA less than a year after Mitsubishi Tanabe Pharma Corporation submitted a New Drug Application. The only other approved treatment specifically for ALS, riluzole, was approved in 1995.

Please click the links on the right to find more information on Radicava and check back often for updates.

Important message about
Radicava prescription coverage

For those who have been denied coverage, we encourage you to request an Independent Medical Review (IMR). This review is conducted by, and under the authority and supervision of, the California Department of Managed Health Care. The process is simple and can be easily completed on-line in just a few minutes. By following this simple process, you will bring much needed awareness of the problem to those within our state government who have the authority to address the issue. By requesting an IMR, you are lending your voice to our efforts to ensure that everyone who wants access to Radicava can have it.

Step 1: Go to the Online IMR Complaint Form. From there, you can complete and submit the request form online, or via mail or fax.

Step 2: Please email or fax a copy of your IMR request form to our Care Services Assistant, Stacy Roberts, to sroberts@alsagoldenwest.org or (818) 865-8066 so that we can track the submissions.

Past Webinars

May 9, 2017 - Webinar: Download Slides / Watch a Recording

May 12, 2017- Webinar:Watch a Recording

The FDA has approved Radicava™, the first new treatment specifically for ALS in 22 years. The drug was approved by the FDA less than a year after Mitsubishi Tanabe Pharma America submitted a New Drug Application. The only other approved treatment specifically for ALS, riluzole, was approved in 1995. Please click the links below to find more information on Radicava and check back often for updates.

Past Webinars

May 9th Webinar:
Download Slides / Watch a Recording

May 12th Webinar:
Watch a Recording

Press Release


FAQ


Connect With Us

When you sign up with our chapter, you’ll learn how you can help secure more funding for ALS research, expand care and resources for people living with this disease and their families, and advance legislative priorities that are important to the entire ALS community.

Sign Up Today